BTK Inhibitor in Diffuse Large B Cell?

There was this paper at Ash where they saw a bunch of responses. We'll see it's a perturbrutinib. I think we may have to revisit a little bit the BTK inhibitor in lean formine general. There is a subset of very well-molecularly defined patients that respond. So, we have to continue to work in this field.